Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28663286 | 1.00 | POLB (0.61) | POLBEPHX1EPHX2ALDH1A1NPC1 | |
| SCHEMBL124227 | 1.00 | POLB (0.61) | POLBEPHX1EPHX2ALDH1A1NPC1 | |
| SCHEMBL3387568 | 0.97 | POLB (0.64) | POLBEPHX1EPHX2ALDH1A1NPC1 | |
| SCHEMBL24606366 | 0.95 | MAPT (0.64) | POLBEPHX1EPHX2ALDH1A1NPC1 | |
| SCHEMBL24383487 | 0.95 | MAPT (0.64) | POLBEPHX1EPHX2ALDH1A1NPC1 | |
| SCHEMBL23946129 | 0.95 | MAPT (0.64) | POLBEPHX1EPHX2ALDH1A1NPC1 | |
| SCHEMBL24383312 | 0.95 | MAPT (0.64) | POLBEPHX1EPHX2ALDH1A1NPC1 | |
| SCHEMBL24202656 | 0.95 | MAPT (0.64) | POLBEPHX1EPHX2ALDH1A1NPC1 | |
| SCHEMBL23946128 | 0.95 | MAPT (0.64) | POLBEPHX1EPHX2ALDH1A1NPC1 | |
| SCHEMBL22790899 | 0.95 | MAPT (0.64) | POLBEPHX1EPHX2ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230157996-A1 | SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF | Shenzhen Bay Laboratory (CN) | 2023-05-25 | — | — | US | disclosed |
| EP-4104837-A2 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | Cancer Research Technology Limited (GB) | 2022-12-21 | — | — | EP | disclosed |
| WO-2022122876-A1 | N-(IMIDAZO[1,2-B]PYRIDAZIN-3-YL)-1-CYCLOHEXYL-2H-INDAZOLE-5-CARBOXAMIDE AND N-(PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-1-CYCLOHEXYL-2H-INDAZOLE-5-CARBOXAMIDE DERIVATIVES AS IRAK4 INHIBITORS FOR THE TREATMENT OF ASTHMA | ASTRAZENECA AB (SE) | 2022-06-16 | — | — | WO | disclosed |
| EP-3442535-B1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2022-06-01 | — | — | EP | disclosed |
| WO-2021115335-A1 | COMPOUND AS CYCLIN-DEPENDENT KINASE 9 INHIBITOR AND USE THEREOF | 石药集团中奇制药技术（石家庄）有限公司 | 2021-06-17 | — | — | WO | disclosed |
| US-20200048261-A1 | PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2020-02-13 | — | — | US | disclosed |
| EP-3141252-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | Vertex Pharmaceuticals Inc. (US) | 2017-03-15 | — | — | EP | disclosed |
| US-20160152614-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED | 2016-06-02 | — | — | US | disclosed |
| US-9345708-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-05-24 | — | — | US | disclosed |
| US-20140296201-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED | 2014-10-02 | — | — | US | disclosed |
| US-7919133-B2 | Substituted cyclopropanecarboxylic acid (3-methyl-cyclohexyl)amide as flavoring substance | SYMRISE GMBH & CO. KG (DE) | 2011-04-05 | — | — | US | disclosed |
| WO-2011008915-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | WO | disclosed |
| EP-1989944-B1 | Substituted cyclopropane carbolic acid(3-methyl-cyclohexyl)amides as taste substances | SYMRISE GMBH & CO KG (DE) | 2010-06-02 | — | — | EP | disclosed |
| WO-2010032856-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | 武田薬品工業株式会社 (JP) | 2010-03-25 | — | — | WO | disclosed |
| CN-101454318-A | Pyridopyrimidine derivatives and their use as pde4 inhibitors | ASTRAZENECA AB (SE) | 2009-06-10 | — | — | CN | disclosed |
| US-20080292763-A1 | Substituted Cyclopropanecarboxylic acid (3-methyl-cyclohexyl)amide as flavoring substance | SYMRISE GMBH & CO. KG (DE) | 2008-11-27 | — | — | US | disclosed |
| US-20080292763-A1 | Substituted Cyclopropanecarboxylic acid (3-methyl-cyclohexyl)amide as flavoring substance | SYMRISE GMBH & CO. KG (DE) | 2008-11-27 | — | — | US | disclosed |
| US-20080292763-A1 | Substituted Cyclopropanecarboxylic acid (3-methyl-cyclohexyl)amide as flavoring substance | SYMRISE GMBH & CO. KG (DE) | 2008-11-27 | — | — | US | disclosed |
| EP-1989944-A1 | Substituted cyclopropane carbolic acid(3-methyl-cyclohexyl)amides as taste substances | Symrise GmbH & Co. KG (DE) | 2008-11-12 | — | — | EP | disclosed |
| CN-101301064-A | Substituted cyclopropanecarboxylic acid (3-methyl-cyclohexyl)amide as flavoring substance | SYMRISE GMBH & CO (DE) | 2008-11-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230157996-A1 | SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF | SSB, EBNA1BP2, PML | POLB 917/4885EPHX1 3689/4885EPHX2 4259/4885 |
| US-20200048261-A1 | PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES | CYP11B2, CYP11B1, DHPS | POLB 217/4885EPHX1 1494/4885EPHX2 1793/4885 |
| US-20140296201-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, IRF3, ACE2 | POLB 21/4885EPHX1 3137/4885EPHX2 4278/4885 |
| US-20080292763-A1 | Substituted Cyclopropanecarboxylic acid (3-methyl-cyclohexyl)amide as flavoring substance | TAS1R1, TAS2R1, TAS1R3 | POLB 4293/4885EPHX1 1402/4885EPHX2 894/4885 |
| US-20160152614-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, IRF3, ACE2 | POLB 21/4885EPHX1 3137/4885EPHX2 4278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.